Medibio Launches Global Corporate Mental Health Product
- Release of first commercially available mental health technology product
- Notable existing support from key Australian companies
- Provide organizations with cost savings by reducing mental health burden
SYDNEY, Australia and MINNEAPOLIS, April 30, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company confirms the launch and release of the Company's Corporate Mental Health for business product and platform (the Platform).
The Platform allows businesses to offer employees the chance to 'check-in on their mental health' through a comprehensive mental health and wellness program that starts with an employee-facing, Mental Health Check-In campaign. The app-based check-in tool is expected to be available in the Google Play and Apple App Store in the first two weeks of May 2018. The mobile app, named Medibio Inform, allows employees of participating businesses to assess their mental health using both traditional assessments and biometric measures.
Providing personal and confidential measures of mental health, the Platform is compatible with heart rate-enabled Fitbit and Garmin devices and soon will support Apple Watch. Businesses are provided with a dashboard of the results at an aggregate level, not tied to individual employees, displayed through data trends to help companies understand the overall mental health of their employee base. Sign-up and registration for the Platform is currently open with the app available in Australia, New Zealand and the US. The Corporate Health product pricing is subject to firm size and structure, but initially ranges between A$15 to A$45 per user.
"Mental illness can have a dramatic effect on a company's productivity. For a company with a workforce of 100,000, the annual loss can exceed 3 million hours.1 The Platform represents a significant advancement in corporate mental health, allowing organizations to move beyond the current ad hoc and highly reactive offerings to a data-driven, evidence-based capability. The human and economic cost of mental health to organizations, and the well documented return on investment makes this one of the most exciting developments in corporate health for decades." stated Peta Slocombe Senior VP of Corporate Health.
With historical participation from a variety of Australian firms, the results of the prior Check-In campaign demonstrated that a measurable and proactive approach to mental health is quickly becoming a priority for many organizations. Amongst them, number one ranked global technical and professional services company, Jacobs Engineering, participated as part of its own health and safety program, BeyondZero®, which supports the mental health and wellness needs of its employees worldwide.
Jack Cosentino, CEO and Managing Director stated, "For the first time, wearable technologies including Garmin and FitBit will be able to track and monitor individuals' circadian heart rhythm (CHR), sleep cycles and activity, to round out an objective understanding of the onset and existence of mental dysfunction. We strongly feel that businesses are strategically positioned to assist individuals in recognizing the need for and accessing resources to treat and manage mental health conditions."
Medibio's Check-in is the first step in a comprehensive Corporate Health offering which includes products and services designed to help employers optimize performance, minimize risk, and better care for their most valuable asset - their people. More information on the Medibio Corporate Health program and Mental Health Check-in registration can be found at http://mentalhealthcheckin.com.
- Creating a mentally healthy workplace. Return on investment analysis. PwC HeadsUp (March 2014)
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au Medibio Shareholder Enquiries: Stephanie Ottens Investor Relations Director Medibio Limited email@example.com T: +61 434 405 400 Australian Media Enquiries: Peter Taylor NWR Communications firstname.lastname@example.org T: +61 (0) 412 036 231
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CET | Pressemelding
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CET | Pressemelding
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera
Mattson Technology Announces Hydrilis™, a Unique High-Productivity Vacuum Wafer Process Platform18.3.2019 17:00:00 CET | Pressemelding
– Up to 4 process chambers and 8 wafer processing stations – – Smallest footprint, highest throughput platform – – Enables any process chamber, any position configuration flexibility – FREMONT, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Mattson Technology, Inc., a leading supplier of advanced process equipment used to manufacture semiconductors, introduces Hydrilis™, the industry’s highest productivity density vacuum transfer platform featuring high throughput on the smallest footprint. The Hydrilis platform can be configured with up to 4 process chambers, or 8 processing stations, for parallel or sequential wafer processing. Any of the paradigmE® family plasma etch process chambers, Suprema® family plasma photoresist strip and hard-mask removal process chambers, Novyka™ family surface treatment process chambers and Novyka family selective chemical dry etch process chambers can all be integrated on the Hydrilis platform. “Throughput per unit area of fab space is one of the key criteria
Minerva Neurosciences to Host Webcast Event on Schizophrenia18.3.2019 13:30:00 CET | Pressemelding
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader. Discussions will feature the following speakers
Infovista Enhances Ipanema SD-WAN with Nextgen Application Intelligence+ and Cloud-Native Orchestration18.3.2019 13:00:00 CET | Pressemelding
PARIS and ASHBURN, Va., March 18, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new cloud-native management and control with next-generation Application Intelligence+ for Ipanema SD-WAN, delivering unmatched application performance across any WAN. Tweet This: Infovista enhances Ipanema SD-WAN with nextgen Application Intelligence+ and cloud native orchestration: https://bit.ly/2ULcKLW #SmarterSDWAN The enterprise network has become the central nervous system of modern digital businesses, and SD-WAN is enabling this digital transformation. Infovista’s Ipanema SD-WAN with new cloud-native management and control of applications tightly combines session-based routing and dynamic path selection of the underlay network with an overlay of deep application visibility and dynamic control of the quality of experience for business-critical applications. Additionally, Ipanema automatically understands application delivery requirements and maintains a
Inspirata and Ohio State University Continue to Break Digital Pathology Barriers18.3.2019 12:30:00 CET | Pressemelding
Columbus, Ohio Columbus, Ohio, March 18, 2019 (GLOBE NEWSWIRE) -- Less than one year ago Inspirata announced that their digital pathology solution was used to make the first-ever primary digital diagnosis in the U.S., initiating a new era in cancer diagnostics. Today, cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced the company with the help of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) has broken another barrier- Inspirata and the OSUCCC – James have scanned over one-million anatomic pathology slides into high resolution whole slide digital images. “This historic accomplishment has demonstrated that it is possible to create large repositories of diagnostic quality prospective and retrospective slides creating imaging data that will accelerate clinical and research efforts,” says Inspirata Scan Center Manager, Trina Shanks, MLT (ACSP), CPC. Inspirata will presen